 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 - Generated Q2 2023 CGuard EPS ...

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

Trial designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates study results and Premarket Approval (PMA) submission in H2 2024, potential U.S. ...

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

InspireMD GAAP EPS of -$0.53 beats by $0.15, revenue of $1.24M beats by $0.24M

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Companys CE Mark certification until mid-March- - Resumed ...

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript

Led byMarshall Wacewith participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 millionfinancing upfront with up to an additional$71.4 milliontied to exercise of milestone-driven warrants TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- ...

InspireMD Announces Private Placement of Up to $113.6 Million

InspireMD Q1 2023 Earnings Preview

Why Are InspireMD Shares Surging Today

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that ...

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Watchers	35,728
52-Wk Low	$0.8064
52-Wk High	$3.77

Market Cap	$70.58M
Volume (M)	6,320.00
52-Wk High	$3.77
52-Wk Low	$0.8064

NSPR InspireMD Inc

About

Feed

News

Fundamentals